[CAS NO. 1231220-79-3]  LY2828360

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1231220-79-3]

Distributor
Catalog
AS948134
Brand
Arctom Scientific
CAS
1231220-79-3

DESCRIPTION [1231220-79-3]

Overview

MDL-
Molecular Weight426.94
Molecular FormulaC22H27ClN6O
SMILESCN1CCN(C2=C3N=C(C4=CC=CC=C4Cl)N(C5CCOCC5)C3=NC(C)=N2)CC1

For research use only. We do not sell to patients.

Summary

LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB 2 ) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.


IC50 & Target

CB 2 [1] .


In Vivo

In WT mice, acute systemic administration of LY2828360 suppresses paclitaxel-induced mechanical and cold allodynia in a dose-dependent manner. LY2828360 produces time-dependent suppressions of paclitaxel-evoked mechanical and cold hypersensitivities and suppression of allodynia is maintained for at least 4.5 h post-injection relative to drug pre-injection levels. At 24 h post-injection, paclitaxel-induced mechanical allodynia has returned to drug pre-injection levels of hypersensitivity. Residual suppression of cold allodynia was absent by 72 h post LY2828360 treatment. Previously chronic administration of LY2828360 blocks the development of tolerance to the antiallodynic effects of morphine in WT but not in CB 2 KO mice. Chronic LY2828360 treatment suppresses paclitaxel-induced mechanical and cold allodynia in WT mice but not in CB 2 KO mice previously render tolerant to morphine [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT01319929 Eli Lilly and Company
Osteoarthritis, Knee
March 2011 Phase 2

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 20.83 mg/mL ( 48.79 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3422 mL 11.7112 mL 23.4225 mL
5 mM 0.4684 mL 2.3422 mL 4.6845 mL
10 mM 0.2342 mL 1.1711 mL 2.3422 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution

* All of the co-solvents are available by MCE.